Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Non-Current Assets readings, the most recent being $1.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 13.19% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, up 13.19%, and an annual FY2025 reading of $1.5 million, up 13.19% over the prior year.
  • Other Non-Current Assets hit $1.5 million in Q4 2025 for Apellis Pharmaceuticals, down from $5.5 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.5 million in Q3 2025, with the low at $898000.0 in Q2 2025.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2023), compared with a mean of $1.5 million.
  • The largest YoY upside for Other Non-Current Assets was 278.69% in 2025 against a maximum downside of 32.48% in 2025.
  • Year by year, Other Non-Current Assets stood at $1.6 million in 2021, then dropped by 18.55% to $1.3 million in 2022, then fell by 12.49% to $1.1 million in 2023, then grew by 21.1% to $1.3 million in 2024, then rose by 13.19% to $1.5 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.5 million, $5.5 million, and $898000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.